Emerging translational therapies for mesothelioma.
Malignant pleural mesothelioma remains a therapeutic and diagnostic problem. Translational mechanisms for treatment of the disease are emerging from newly learned characteristics of the tumor on a molecular, cellular, and extracellular basis. Although slow to reach the clinical arena, these potential strategies do show proof of principle in the in vitro and in vivo settings, and some, including adenoviral molecular chemotherapy, have completed phase I testing. This review describes the rationale and status of these newer treatment ideas.
Pass
H I
HI
Karmanos Cancer Institute, Wayne State University, Detroit, MI, USA. pass@cardiology.harper.wayne.edu
Robinson
B W
BW
Testa
J R
JR
Carbone
M
M
D000256:Adenoviridae / Q000235:genetics; D000276:Adjuvants, Immunologic / Q000627:therapeutic use; D000818:Animals; D000970:Antineoplastic Agents / Q000627:therapeutic use; D019898:Autocrine Communication; D017321:Clinical Trials, Phase I as Topic; D018390:Gene Targeting; D005822:Genetic Vectors; D006801:Humans; D008654:Mesothelioma / Q000175:diagnosis / Q000235:genetics / Q000276:immunology / Q000473:pathology / Q000628:therapy*; D019899:Paracrine Communication
D000276:Adjuvants, Immunologic; D000970:Antineoplastic Agents